A Model of the Cost-effectiveness of Intensity-modulated Radiotherapy in Comparison with Three-dimensional Conformal Radiotherapy for the Treatment of Localised Prostate Cancer

Clinical Oncology

Volumn 24, Issue 10, 2012, Pages

  Hummel, S R ^a   Stevenson, M D ^a   Simpson, E L ^a   Staffurth, J ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cost effectiveness; Costs; Intensity modulation; Local therapy; Prostatic neoplasms; Radiotherapy

Indexed keywords

GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DRUG COST; GASTROINTESTINAL TOXICITY; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; THREE DIMENSIONAL CONFORMAL RADIOTHERAPY;

COST-BENEFIT ANALYSIS; GASTROINTESTINAL DISEASES; HUMANS; MALE; MODELS, ECONOMIC; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84868303908     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.09.003     Document Type: Article

References (36)

1. National Collaborating Centre for Cancer. Prostate cancer: diagnosis and treatment. NICE full guideline CG58. Cardiff: National Collaborating Centre for Cancer, 2008.
2. Sutcliffe P, Hummel S, Simpson E, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Technology Assessment Report commissioned by the NHS R&D HTA Programme, 2007.
3. Peeters S.T.H. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
4. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
5. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92:488-498.
6. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
7. Hummel S., Paisley S., Currie E., Morgan A., Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer. Health Technology Assessment 2003, 7.
8. Mayles W.P. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol (R Coll Radiol) 2010, 22:636-642.
9. Konski A., Watkins-Bruner D., Feigenberg S., et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66(2):408-415.
10. Pearson S., Ladapo J., Prosser L. Intensity modulated radiation therapy (IMRT) for localized prostate cancer 2007, Institute for Clinical and Economic Review, Massachusetts General Hospital Institute for Technology Assessment, Massachusetts.
11. Hummel S., Simpson E.L., Hemingway P., Stevenson M.D., Rees A. Intensity modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment 2011, 14:1-137.
12. Kupelian P.A.R. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002, 53:904-912.
13. Kupelian P.A., Thakkar V.V., Khuntia D., et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005, 63:1463-1468.
14. Vora S.A., Wong W.W., Schild S.E., Ezzell G.A., Halyard M.Y. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:1053-1058.
15. Morgan P., Ruth K., Horwitz E., et al. A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: toxicity and outcomes. Int J Radiat Oncol Biol Phys 2007, 69:S319.
16. Kestin L.L., Vicini F.A., Martinez A.A. Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys 2002, 53:304-315.
17. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTROPhoenix Consensus Conference. Int J Radiat Biol Phys 2006, 65:965-974.
18. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
19. Collins R., Fenwick E., Trowman R., et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technology Assessment 2007, 11(2):1-198.
20. Office for National Statistics. Interim life tables. Expectation of life United Kingdom Males. Office for National Statistics, 2009. Available at: http://www.gad.gov.uk/Demography%2520Data/Life%2520Tables/Interim_life_tables.html.
21. Van der Werf E., Lievens Y., Verstraete J., Pauwels K., Van den B.W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother Oncol 2009, 93:137-140.
22. Curtis L. Unit costs of health and social care. PSSRU, 2008.
23. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
24. Ara R., Brazier J.E. Populating an economic model with health state utility values: moving toward better practice. Value in Health 2010, 13:509-518.
25. Shimizu F.F. Factors associated with variation in utility scores among patients with prostate cancer. Value Health 2008, 11:1190-1193.
26. Sullivan P.W., Mulani P.M., Fishman M., et al. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res 2007, 16:571-575.
27. Guide to the methods of technology appraisal 2008, National Institute for Health and Clinical Excellence (NICE), NICE, London.
28. Williams M.V., Hoole A.C., Dean J.C., et al. IMRT can be faster to deliver than conformal radiotherapy. Radiother Oncol 2010, 95:257-258.
29. Claxton K., Sculpher M., McCabe C., et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005, 14:339-347.
30. Martinez A., Yan D., Brabbins D., et al. Acute and chronic toxicity of adaptive image guided radiation therapy (A-IGRT) delivered with 3D-conformal technique (3D-CRT) vs. intensity modulation (IMRT) in 728 prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:S317.
31. Sharma N., Li T., Horwitz E., Pollack A., Buyyounouski M. Intensity modulated radiation therapy reduces gastrointestinal morbidity in patients treated with androgen deprivation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007, 69:S10.
32. Sanguineti G., Cavey M.L., Endres E.J., et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate only radiotherapy to 76 Gy?. Strahlenther Onkol 2006, 182:543-549.
33. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13(1):43-54.
34. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer; a randomised trial. Lancet 1999, 353:267-272.
35. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010, 22(8):643-657.
36. Konski A. Cost-effectiveness of intensity-modulated radiation therapy. Expert Rev Pharmacoecon Outcomes Res 2005, 5:137-140.